Abstract:Background & aims: The effectiveness of immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) is limited by treatment resistance. However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in resistance to anti-PD-1 therapy in HCC. Methods: Gene expression in HCC specimens from 10 patients receiving anti-PD-1 therapy was identified by RNA-sequencing. A total of 404 HCC samples from tissue microarrays were analyzed by immunohistochemistry. Transgenic mice (Alb-Cre/Trp53fl/fl) received hydrodynamic tail vein injections of a CRKL-overexpressing vector. Mass cytometry by time of flight was used to profile the proportion and status of different immune cell lineages in the mouse tumor tissues. Results: CRKL was identified as a candidate anti-PD-1-resistance gene using a pooled genetic screen. CRKL overexpression nullifies anti-PD-1 treatment efficacy by mobilizing tumor-associated neutrophils (TANs), which block the infiltration and function of CD8+ T cells. PD-L1+ TANs were found to be an essential subset of TANs that were regulated by CRKL expression and display an immunosuppressive phenotype. Mechanistically, CRKL inhibits APC (adenomatous polyposis coli)-mediated proteasomal degradation of β-catenin by competitively decreasing Axin1 binding, and thus promotes VEGFα and CXCL1 expression. Using human HCC samples, we verified the positive correlations of CRKL/β-catenin/VEGFα and CXCL1. Targeting CRKL using CRISPR-Cas9 gene editing (CRKL knockout) or its downstream regulators effectively restored the efficacy of anti-PD-1 therapy in an orthotopic mouse model and a patient-derived organotypic tumor spheroid model. Conclusions: Activation of the CRKL/β-catenin/VEGFα and CXCL1 axis is a critical obstacle to successful anti-PD-1 therapy. Therefore, CRKL inhibitors combined with anti-PD-1 could be useful for the treatment of HCC. Impact and implications: Here, we found that CRKL was overexpressed in anti-PD-1-resistant hepatocellular carcinoma (HCC) and that CRKL upregulation promotes anti-PD-1 resistance in HCC. We identified that upregulation of the CRKL/β-catenin/VEGFα and CXCL1 axis contributes to anti-PD-1 tolerance by promoting infiltration of tumor-associated neutrophils. These findings support the strategy of bevacizumab-based immune checkpoint inhibitor combination therapy, and CRKL inhibitors combined with anti-PD-1 therapy may be developed for the treatment of HCC.

CRKL Knockdown Promotes in Vitro Proliferation, Migration and Invasion, in Vivo Tumor Malignancy and Lymph Node Metastasis of Murine Hepatocarcinoma Hca-P Cells

Downregulation of CRKL Expression Can Inhibit Tumorigenesis in Colon Cancer.

CRKL Promotes Hepatocarcinoma Through Enhancing Glucose Metabolism of Cancer Cells Via Activating PI3K/Akt.

CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma

Myeloid-intrinsic cell cycle-related kinase drives immunosuppression to promote tumorigenesis

Rcl1 Suppresses Tumor Progression of Hepatocellular Carcinoma: A Comprehensive Analysis of Bioinformatics and in Vitro Experiments

Inhibition of KLHL21 Prevents Cholangiocarcinoma Progression Through Regulating Cell Proliferation and Motility, Arresting Cell Cycle and Reducing Erk Activation

Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy

Cr6-Interacting Factor 1 Inhibits Invasiveness By Suppressing Tgf-Beta-Mediated Epithelial-Mesenchymal Transition In Hepatocellular Carcinoma

Transcriptomic Analyses of Chemokines Reveal That Down-Regulation of XCR1 is Associated with Advanced Hepatocellular Carcinoma

CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer

Identification of CRKL as an oncogenic biomarker for prognosis and immunotherapy in melanoma, and its potential molecular mechanism

Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway

The long noncoding RNA PCAT-1 links the microRNA miR-215 to oncogene CRKL-mediated signaling in hepatocellular carcinoma

SH3 domain‐binding kinase 1 promotes proliferation and inhibits apoptosis of cervical cancer via activating the Wnt/β‐catenin and Raf/ERK1/2 signaling pathways

CircCRIM1 Promotes Hepatocellular Carcinoma Proliferation and Angiogenesis by Sponging miR-378a-3p and Regulating SKP2 Expression

1052 MicroRNA-218 Inhibits Cell Cycle Progression and Promotes Apoptosis in Colon Cancer Cells by Downregulating Oncogene BMI1

Depletion of MLKL inhibits invasion of radioresistant nasopharyngeal carcinoma cells by suppressing epithelial-mesenchymal transition

Down-regulation of CXCR7 Inhibits the Growth and Lung Metastasis of Human Hepatocellular Carcinoma Cells with Highly Metastatic Potential

T‐LAK Cell‐originated Protein Kinase is Essential for the Proliferation of Hepatocellular Carcinoma SMMC‐7721 Cells

Downregulation of CCR1 Inhibits Human Hepatocellular Carcinoma Cell Invasion